Source comparison
Best BPC-157 Dosage Inflammation 2026: Protocol Comparison
Systemic/Metabolic Inflammation 250–350mcg Subcutaneous (abdominal) Once daily 21–28 days 25–30% TNF-α, IL-6 reduction Joint/Musculoskeletal (Localized) 400–600mcg Subcutaneous (peri-articular) 28–42 days 35–45% localized cytokine reduction Joint (Intra-Articu
This comparison does not assign a generated winner or score.
- Systemic/Metabolic Inflammation
- 250–350mcg
- Subcutaneous (abdominal)
- Once daily
- 21–28 days
- 25–30% TNF-α, IL-6 reduction
- Joint/Musculoskeletal (Localized)
- 400–600mcg
- Subcutaneous (peri-articular)
- 28–42 days
- 35–45% localized cytokine reduction
- Joint (Intra-Articular Protocol)
- 500mcg–1mg per joint
- Intra-articular injection
- 2–3x weekly
- 4–6 weeks
- 40–50% synovial fluid inflammatory markers
- Gastrointestinal Barrier Repair
- 250mcg SC + 750mcg oral
- Combined subcutaneous + oral
- Daily (both routes)
- 21–35 days
- 40–45% intestinal permeability improvement
- Acute Injury (within 12 hours)
- 500mcg initial, 300mcg daily
- Subcutaneous (injury-proximate)
- Initial dose + daily maintenance
- 14–21 days
- 35–40% acute-phase cytokine reduction
- Chronic Tendinopathy
- 400–500mcg
- Subcutaneous (tendon-proximate)
- 42–56 days
- 30–35% pain marker reduction, collagen density improvement